Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Fosun International Ltd, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Novartis May Sell US Generic Pill Business 18
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20
Venture Financing 21
Ambrx Raises USD45 Million in Venture Financing 21
BeyondSpring Pharma Raises USD20 Million in Series A Financing 23
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
Private Equity 26
Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26
Ardian May Sell Riemser Pharma for USD494.3 Million 28
BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30
Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31
Partnerships 33
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33
Arix Bioscience and Fosun International Enter into Agreement 34
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36
Kite Pharma Forms Joint Venture with Fosun Pharma 37
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 38
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43
Licensing Agreements 44
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46
Equity Offering 47
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49
Chindex to Raise USD38.2 Million in Private Placement of Shares 51
Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 57
Fosun International Announces Rights Offering Of Shares For Up To US$668.4 Million 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 60
Fosun International Completes IPO For US$512 Million 61
Debt Offering 63
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69
Asset Transactions 70
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70
Acquisition 71
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78
Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 80
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Fosun International Ltd – Key Competitors 87
Fosun International Ltd – Key Employees 88
Fosun International Ltd – Locations And Subsidiaries 89
Head Office 89
Other Locations & Subsidiaries 89
Recent Developments 91
Corporate Communications 91
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 91
Appendix 94
Methodology 94
About GlobalData 94
Contact Us 94
Disclaimer 94
Fosun International Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fosun International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fosun International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novartis May Sell US Generic Pill Business 18
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 20
Ambrx Raises USD45 Million in Venture Financing 21
BeyondSpring Pharma Raises USD20 Million in Series A Financing 23
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 26
Ardian May Sell Riemser Pharma for USD494.3 Million 28
BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 30
Baring Private Equity Asia May Acquire Controlling Stake in Symbiotec Pharmalab from Actis Capital 31
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 33
Arix Bioscience and Fosun International Enter into Agreement 34
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 35
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 36
Kite Pharma Forms Joint Venture with Fosun Pharma 37
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 38
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 39
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 40
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 41
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 42
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 43
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 45
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 46
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 47
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 49
Chindex to Raise USD38.2 Million in Private Placement of Shares 51
Fosun International Plans to Raise up to USD1.2 Billion in Public Offering of Shares 52
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 53
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 54
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 55
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 56
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 57
Fosun International Announces Rights Offering Of Shares For Up To US$668.4 Million 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 60
Fosun International Completes IPO For US$512 Million 61
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 63
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 64
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 65
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 66
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 67
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 68
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 69
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 70
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 71
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 72
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 74
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 75
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 77
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 78
Fosun Increases Offer Price to Acquire Espirito Santo Saude for USD586 Million 79
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 80
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Fosun International Ltd, Key Competitors 87
Fosun International Ltd, Key Employees 88
Fosun International Ltd, Other Locations 89
Fosun International Ltd, Subsidiaries 89
List of Figures
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Fosun International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Fosun International Ltd, Medical Devices Deals, 2012 to YTD 2018 12
